Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 320-329

  Zaunders, John J ^a,b   Cunningham, Philip H ^a   Kelleher, Anthony D ^d   Kaufmann, Gilbert R ^a   Jaramillo, Angel B ^a   Wright, Rowanne ^a   Smith, Don ^a   Grey, Pat ^a   Vizzard, Jeanette ^c   Carr, Andrew ^a,b   Cooper, David A ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CYTOTOXIC LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DNA, VIRAL; DRUG THERAPY, COMBINATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIREMIA; ZIDOVUDINE;

EID: 0033503076     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314880     Document Type: Article

References (48)

1. 1. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
2. 2. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viraemia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
3. 3. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS 1991;5:1-14.
4. 4. Zaunders J, Carr A, McNally L, Penny R, Cooper D. Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. AIDS 1995;9:561-6.
5. 5. Cooper DA, Tindall B, Wilson EJ, Imric AA, Penny R. Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. J Infect Dis 1988;157:889-96.
6. 6. Gaines H, von Sydow MAE, von Stedingk LV, et al. Immunological changes in primary HIV-1 infection. AIDS 1990;4:995-9.
7. 7. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50.
8. 8. Keet IP, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7:51-7.
9. 9. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299:154-7.
10. 10. Vanhems P, Lambert J, Cooper DA, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998;26:323-9.
11. 11. Kinloch-de Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333:408-13.
12. 12. Perrin L, Rakik A, Yerly S, et al. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS 1996;10:1233-7.
13. 13. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175: 1051-5.
14. 14. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998;352:199-200.
15. 15. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95:8869-73.
16. 16. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
17. 17. Sprent J. Immunological memory. Curr Opin Immunol 1997;9:371-9.
18. 18. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki67. J Immunol 1984;133:1710-5.
19. 19. Kagi D, Hengartner H. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr Opin Immunol 1996;8:472-7.
20. 20. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179:527-37.
21. 21. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
22. 22. Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nat Med 1995;1:674-80.
23. 23. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-20.
24. 24. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998;4:215-21.
25. 25. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
26. 26. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
27. 27. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
28. 28. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
29. 29. Pakker NG, Kroon EDMB, Roos MTL, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 1999;13:203-12.
30. 30. Giorgi JV, Boumsell L, Autran B. Reactivity of workshop T-cell section mAb with circulating CD4+ and CD8+ T cells in HIV disease and following in vitro activation. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. Leukocyte Typing V. Vol. 1. Oxford: Oxford University Press, 1995: 446-61.
31. 31. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+ CD38+ CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1 infected patients. AIDS 1996;10:827-34.
32. 32. Cossarizza A, Ortolani C, Mussini C, et al. Massive activation of immune cells with intact T cell repertoire in acute human immunodeficiency virus sydrome. J Infect Dis 1995;172:105-12.
33. 33. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-6.
34. 34. Bell EB, Sparshott SM, Bunce C. CD4+ T-cell memory, CD45R subsets and the persistence of antigen a unifying concept. Immunol Today 1998;19: 60-4.
35. 35. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
36. 36. Bass HZ, Hardy WD, Mitsuyasu RT, Wang YX, Cumberland W, Fahey JL. Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. J Acquir Immune Defic Syndr 1992;5: 890-7.
37. 37. Bouscarat F, Levacher-Clergeot M, Dazza M-C, et al. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996;12:17-24.
38. 38. Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14:561-9.
39. 39. Bouscarat F, Levacher M, Landman R, et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998;12:1267-73.
40. 40. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:332-40.
41. 41. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
42. 42. Lynne JE, Schmid I, Matud JL, et al. Major expansions of select CD8+ subsets in acute Epstein-Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998;177:1083-7.
43. 43. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-91.
44. 44. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276: 960-4.
45. 45. Dalod M, Fiorentino S, Delamare C, et al. Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cells counts: correlation with various parameters of disease progression. AIDS Res Hum Retroviruses 1996;12:497-506.
46. 46. Fiorentino S, Dalod M, Olive D, Guillet J-G, Gomard E. Predominant involvement of CD8+ CD28 lymphocytes in human immunodeficiency virus specific cytotoxic activity. J Virol 1996;70:2022-6.
47. 47. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188:233-45.
48. 48. Tenner-Racz K, Stellbrink HJ, van Lunzen J, et al. The unenlarged lymph nodes of HIV-1 infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J Exp Med 1998;187: 949-59.